Budigalimab & HIV: PD-1 Blockade Safety & Early Effects
Budigalimab Shows Promise in Delaying HIV Viral Rebound During Treatment Interruption In a significant development for HIV research, a new study indicates that the experimental drug budigalimab may offer a novel approach to controlling the virus. Early trial results reveal that budigalimab, a PD-1 inhibitor, was well-tolerated by participants and demonstrated the ability to delay … Read more